Pancreatic Cancer Research

ResearcherChinese Academy of Medical Sciences & Peking Union Medical CollegeActive in the last 2 years

Junya Peng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0278-7057; OpenAlex author ID A5046259983. Sources: OpenAlex.

Their work

Papers
9 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
36
Papers, trials and grants by year

2019: 3 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: none · 2024: 1 paper · 2025: none · 2026: 2 papers

Papers 9

  1. A conserved re-epithelialization program underlies malignancy in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ccell.2026.03.021↗
  2. Bioengineering advances in pancreatic cancer organoids for reproducible tumor microenvironment modeling. Co-author DOI 10.1016/j.isci.2026.116487↗
  3. Pancreatic cancer cell-derived migrasomes promote cancer progression by fostering an immunosuppressive tumor microenvironment. First author DOI 10.1016/j.canlet.2024.217289↗
  4. Interleukin-17 activates and synergizes with the notch signaling pathway in the progression of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.canlet.2021.03.003↗
  5. Mutant Kras co-opts a proto-oncogenic enhancer network in inflammation-induced metaplastic progenitor cells to initiate pancreatic cancer. Co-author DOI 10.1038/s43018-020-00134-z↗
  6. CXCL5 overexpression predicts a poor prognosis in pancreatic ductal adenocarcinoma and is correlated with immune cell infiltration. Co-author DOI 10.7150/jca.40517↗
  7. Pancreatic cancer-educated macrophages protect cancer cells from complement-dependent cytotoxicity by up-regulation of CD59. Co-author DOI 10.1038/s41419-019-2065-4↗
  8. Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41422-019-0195-y↗
  9. Author Correction: Single-cell RNA-seq highlights intra-tumoral heterogeneity and malignant progression in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41422-019-0212-1↗

Closest collaborators

The 25 strongest of 36 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenming Wu · 5 shared papers, 2019–2026 · strength 0.71
  2. Yupei Zhao · 6 shared papers, 2019–2026 · strength 0.70
  3. Qiaofei Liu · 3 shared papers, 2019–2024 · strength 0.39
  4. Ronghua Zhang · 3 shared papers, 2019–2024 · strength 0.39
  5. Renyu Chen · 1 shared paper, 2026 · strength 0.36
  6. Menghua Dai · 3 shared papers, 2019–2026 · strength 0.35
  7. Meilian Zhuo · 2 shared papers, 2021–2026 · strength 0.30
  8. Mo Chen · 2 shared papers, 2021–2026 · strength 0.30
  9. Charles J. David · 2 shared papers, 2021–2026 · strength 0.30
  10. Quan Liao · 3 shared papers, 2019–2020 · strength 0.28
  11. Ming Cui · 2 shared papers, 2020–2024 · strength 0.28
  12. Tong Li · 2 shared papers, 2020–2024 · strength 0.28
  13. Wenze Wang · 3 shared papers, 2019–2021 · strength 0.28
  14. Mengyi Wang · 2 shared papers, 2019–2020 · strength 0.21
  15. Xianlin Han · 1 shared paper, 2026 · strength 0.21
  16. Ruizhe He · 1 shared paper, 2026 · strength 0.21
  17. Mingyang Liu · 1 shared paper, 2026 · strength 0.21
  18. Weibin Wang · 1 shared paper, 2026 · strength 0.21
  19. Hao Chen · 2 shared papers, 2019–2021 · strength 0.18
  20. Yalu Zhang · 1 shared paper, 2024 · strength 0.18
  21. Sen Yang · 1 shared paper, 2024 · strength 0.18
  22. Junyi Gao · 1 shared paper, 2024 · strength 0.18
  23. Quan Liao · 1 shared paper, 2024 · strength 0.18
  24. Jorg H. Kleeff · 1 shared paper, 2024 · strength 0.18
  25. Yusheng Chen · 2 shared papers, 2019 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.